News & Events

News

Fibralign Announces CE Mark Approval for BioBridge®

Fibralign Announces CE Mark Approval for BioBridge®

European approval for novel device supporting surgical treatment of lymphedema September 14, 2020 (Union City, CA) – Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first...

read more

Conferences

Fibralign and its research collaborators have made over 50 presentations related to BioBridge and Nanoweave scientific findings at international leading medical research conferences over the previous two years.
While these conferences have largely paused during 2020 due to the pandemic, we will post upcoming presentations when these conferences return to schedule.